Janney Montgomery Scott LLC Has $36.05 Million Holdings in Bristol-Myers Squibb Co (BMY)

Janney Montgomery Scott LLC lessened its stake in Bristol-Myers Squibb Co (NYSE:BMY) by 1.7% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 580,670 shares of the biopharmaceutical company’s stock after selling 10,048 shares during the quarter. Janney Montgomery Scott LLC’s holdings in Bristol-Myers Squibb were worth $36,048,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. BlackRock Inc. boosted its stake in shares of Bristol-Myers Squibb by 7.2% during the 2nd quarter. BlackRock Inc. now owns 111,913,559 shares of the biopharmaceutical company’s stock valued at $6,193,296,000 after buying an additional 7,517,623 shares during the last quarter. Janus Henderson Group PLC boosted its stake in shares of Bristol-Myers Squibb by 114.5% during the 2nd quarter. Janus Henderson Group PLC now owns 6,922,917 shares of the biopharmaceutical company’s stock valued at $383,119,000 after buying an additional 3,695,485 shares during the last quarter. Point72 Asset Management L.P. boosted its stake in shares of Bristol-Myers Squibb by 4,455.9% during the 2nd quarter. Point72 Asset Management L.P. now owns 3,416,898 shares of the biopharmaceutical company’s stock valued at $189,091,000 after buying an additional 3,341,898 shares during the last quarter. Schroder Investment Management Group boosted its stake in shares of Bristol-Myers Squibb by 419.0% during the 2nd quarter. Schroder Investment Management Group now owns 3,851,748 shares of the biopharmaceutical company’s stock valued at $213,003,000 after buying an additional 3,109,664 shares during the last quarter. Finally, Massachusetts Financial Services Co. MA boosted its stake in shares of Bristol-Myers Squibb by 44.3% during the 3rd quarter. Massachusetts Financial Services Co. MA now owns 9,460,148 shares of the biopharmaceutical company’s stock valued at $587,287,000 after buying an additional 2,903,920 shares during the last quarter. Hedge funds and other institutional investors own 72.54% of the company’s stock.

Shares of NYSE BMY opened at $52.81 on Friday. Bristol-Myers Squibb Co has a 1-year low of $46.94 and a 1-year high of $70.05. The company has a current ratio of 1.53, a quick ratio of 1.40 and a debt-to-equity ratio of 0.41. The firm has a market capitalization of $83.81 billion, a price-to-earnings ratio of 17.54, a P/E/G ratio of 1.43 and a beta of 1.08.

Bristol-Myers Squibb (NYSE:BMY) last issued its earnings results on Thursday, October 25th. The biopharmaceutical company reported $1.09 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.91 by $0.18. Bristol-Myers Squibb had a return on equity of 47.89% and a net margin of 6.50%. The firm had revenue of $5.69 billion for the quarter, compared to analyst estimates of $5.72 billion. Sell-side analysts anticipate that Bristol-Myers Squibb Co will post 3.88 EPS for the current fiscal year.

The business also recently announced a quarterly dividend, which was paid on Thursday, November 1st. Shareholders of record on Friday, October 5th were given a $0.40 dividend. This represents a $1.60 annualized dividend and a yield of 3.03%. The ex-dividend date of this dividend was Thursday, October 4th. Bristol-Myers Squibb’s dividend payout ratio is presently 53.16%.

Several equities research analysts recently issued reports on the company. ValuEngine raised Bristol-Myers Squibb from a “sell” rating to a “hold” rating in a research report on Saturday, July 14th. Credit Suisse Group upped their price target on Bristol-Myers Squibb from $58.00 to $61.00 and gave the company a “neutral” rating in a research report on Friday, July 27th. BMO Capital Markets reissued a “hold” rating on shares of Bristol-Myers Squibb in a research report on Sunday, July 22nd. Morgan Stanley dropped their price target on Bristol-Myers Squibb from $63.00 to $59.00 and set a “hold” rating on the stock in a research report on Tuesday. Finally, Jefferies Financial Group set a $58.00 price target on Bristol-Myers Squibb and gave the company a “hold” rating in a research report on Sunday, July 15th. Two investment analysts have rated the stock with a sell rating, twelve have assigned a hold rating and seven have given a buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $62.48.

ILLEGAL ACTIVITY NOTICE: “Janney Montgomery Scott LLC Has $36.05 Million Holdings in Bristol-Myers Squibb Co (BMY)” was published by WKRB News and is the property of of WKRB News. If you are accessing this story on another site, it was copied illegally and reposted in violation of U.S. & international trademark & copyright law. The correct version of this story can be read at https://www.wkrb13.com/2018/11/09/janney-montgomery-scott-llc-has-36-05-million-holdings-in-bristol-myers-squibb-co-bmy.html.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products worldwide. The company offers drugs in various therapeutic classes, such as oncology; cardiovascular; immunoscience; and virology, including human immunodeficiency virus (HIV) infection.

Recommended Story: Why do corrections happen?

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Co (NYSE:BMY).

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply